{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:46:37Z","timestamp":1773297997964,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T00:00:00Z","timestamp":1589414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T00:00:00Z","timestamp":1589414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s40273-020-00923-5","type":"journal-article","created":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T01:02:31Z","timestamp":1589418151000},"page":"971-980","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Economic Evaluation of Cannabinoid Oil for Dravet Syndrome: A Cost-Utility Analysis"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2501-1641","authenticated-orcid":false,"given":"Jesse","family":"Elliott","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bl\u00e1thnaid","family":"McCoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2356-2300","authenticated-orcid":false,"given":"Tammy","family":"Clifford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8374-6542","authenticated-orcid":false,"given":"Beth K.","family":"Potter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2289-9139","authenticated-orcid":false,"given":"George A.","family":"Wells","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3492-2268","authenticated-orcid":false,"given":"Doug","family":"Coyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,14]]},"reference":[{"issue":"5","key":"923_CR1","doi-asserted-by":"crossref","first-page":"e1310","DOI":"10.1542\/peds.2015-1807","volume":"136","author":"YW Wu","year":"2015","unstructured":"Wu YW, Sullivan J, McDaniel SS, et al. Incidence of Dravet syndrome in a US population. Pediatrics. 2015;136(5):e1310\u2013e13151315.","journal-title":"Pediatrics"},{"key":"923_CR2","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/B978-0-444-52891-9.00065-8","volume":"111","author":"C Dravet","year":"2013","unstructured":"Dravet C, Oguni H. Dravet syndrome (severe myoclonic epilepsy in infancy). Handb Clin Neurol. 2013;111:627\u201333.","journal-title":"Handb Clin Neurol"},{"issue":"Suppl. 2","key":"923_CR3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1528-1167.2011.02994.x","volume":"52","author":"C Dravet","year":"2011","unstructured":"Dravet C. The core Dravet syndrome phenotype. Epilepsia. 2011;52(Suppl. 2):3\u20139.","journal-title":"Epilepsia"},{"issue":"6","key":"923_CR4","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","volume":"51","author":"P Kwan","year":"2010","unstructured":"Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51(6):1069\u201377.","journal-title":"Epilepsia"},{"issue":"2","key":"923_CR5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.14581\/jer.14010","volume":"4","author":"SK Lee","year":"2014","unstructured":"Lee SK. Old versus new: why do we need new antiepileptic drugs? J Epilepsy Res. 2014;4(2):39\u201344.","journal-title":"J Epilepsy Res"},{"issue":"8","key":"923_CR6","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1111\/epi.16099","volume":"60","author":"A Strzelczyk","year":"2019","unstructured":"Strzelczyk A, Schubert-Bast S, Bast T, et al. A multicenter, matched case-control analysis comparing burden-of-illness in Dravet syndrome to refractory epilepsy and seizure remission in patients and caregivers in Germany. Epilepsia. 2019;60(8):1697\u2013710.","journal-title":"Epilepsia"},{"key":"923_CR7","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1017\/S0012162206001629","volume":"48","author":"KJ Nolan","year":"2006","unstructured":"Nolan KJ, Camfield CS, Camfield PR. Coping with Dravet syndrome: parental experiences with a catastrophic epilepsy. Dev Med Child Neurol. 2006;48:761\u20135.","journal-title":"Dev Med Child Neurol"},{"key":"923_CR8","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.ejpn.2012.04.008","volume":"16","author":"P Camfield","year":"2012","unstructured":"Camfield P, Camfield C, Nolan K. Helping families cope with the devastation of Dravet syndrome. Eur J Paediatr Neurol. 2012;16:S9\u201312.","journal-title":"Eur J Paediatr Neurol"},{"key":"923_CR9","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.yebeh.2018.01.003","volume":"80","author":"JD Campbell","year":"2018","unstructured":"Campbell JD, Whittington MD, Kim CH, et al. Assessing the impact of caring for a child with Dravet syndrome: results of a caregiver survey. Epilepsy Behav. 2018;80:152.","journal-title":"Epilepsy Behav"},{"issue":"1","key":"923_CR10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejpn.2015.11.003","volume":"20","author":"N Hartmann","year":"2016","unstructured":"Hartmann N, Neininger MP, Bernhard MK, et al. Use of complementary and alternative medicine (CAM) by parents in their children and adolescents with epilepsy\u2014prevelance, predictors and parents\u2019 assessment. Eur J Paediatr Neurol. 2016;20(1):11\u20139.","journal-title":"Eur J Paediatr Neurol"},{"key":"923_CR11","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.socscimed.2017.08.003","volume":"190","author":"EJ Sobo","year":"2017","unstructured":"Sobo EJ. Parent use of cannabis for intractable pediatric epilepsy: everyday empiricism and the boundaries of scientific medicine. Soc Sci Med. 2017;190:190\u20138.","journal-title":"Soc Sci Med"},{"issue":"1","key":"923_CR12","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/epi.14608","volume":"60","author":"J Elliott","year":"2019","unstructured":"Elliott J, DeJean D, Clifford T, et al. Cannabis-based products for pediatric epilepsy: a systematic review. Epilepsia. 2019;60(1):6\u201319.","journal-title":"Epilepsia"},{"key":"923_CR13","volume-title":"Guidelines for the economic evaluation of health technologies: Canada (4th edition)","author":"Canadian Agency for Drugs and Technologies in Health","year":"2017","unstructured":"Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada (4th edition). Ottawa: Canadian Agency for Drugs and Technologies in Health; 2017."},{"issue":"10","key":"923_CR14","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s40273-019-00816-2","volume":"37","author":"J Elliott","year":"2019","unstructured":"Elliott J, van Katwyk S, McCoy B, et al. Decision models for assessing the cost-effectiveness of treatments for pediatric drug-resistant epilepsy: a systematic review of economic evaluations. Pharmacoeconomics. 2019;37(10):1261\u201376.","journal-title":"Pharmacoeconomics"},{"key":"923_CR15","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jval.2013.02.010","volume":"16","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Value Health. 2013;16:e1\u20135.","journal-title":"Value Health"},{"key":"923_CR16","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1007\/s40273-018-0669-7","volume":"36","author":"J Elliott","year":"2018","unstructured":"Elliott J, McCoy B, Clifford T, et al. Economic evaluation of stiripentol for Dravet syndrome: a cost-utility analysis. Pharmacoeconomics. 2018;36:1253\u201361.","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"923_CR17","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/acn3.621","volume":"5","author":"B McCoy","year":"2018","unstructured":"McCoy B, Wang L, Zak M, et al. A prospective open-label trial of a CBD\/THC cannabis oil in Dravet syndrome. Ann Clin Transl Neurol. 2018;5(9):1077\u201388.","journal-title":"Ann Clin Transl Neurol"},{"key":"923_CR18","doi-asserted-by":"crossref","first-page":"716","DOI":"10.3389\/fneur.2019.00716","volume":"10","author":"RJ Huntsman","year":"2019","unstructured":"Huntsman RJ, Tang-Wai R, Alcorn J, et al. Dosage related efficacy and tolerability of cannabidiol in children with treatment-resistant epileptic encephalopathy: preliminary results of the CARE-E study. Front Neurol. 2019;10:716.","journal-title":"Front Neurol"},{"key":"923_CR19","unstructured":"Canadian Paediatric Society, Canadian Paediatric Endocrine Group, College of Family Physicians of Canada, et al. WHO Growth charts for Canada. 2014 [cited 2019]. https:\/\/www.dietitians.ca\/growthcharts. Accessed 8 May 2020."},{"key":"923_CR20","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13643-018-0761-2","volume":"7","author":"J Elliott","year":"2018","unstructured":"Elliott J, DeJean D, Clifford T, et al. Cannabis for pediatric epilepsy: protocol for a living systematic review. Syst Rev. 2018;7:95.","journal-title":"Syst Rev"},{"key":"923_CR21","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.eplepsyres.2015.03.012","volume":"113","author":"Y Inoue","year":"2015","unstructured":"Inoue Y, Ohtsuka Y. Long-term safety and efficacy of stiripentol for the treatment of Dravet syndrome: a multicenter, open-label study in Japan. Epilepsy Res. 2015;113:90\u20137.","journal-title":"Epilepsy Res"},{"issue":"4","key":"923_CR22","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/0272989X03255922","volume":"23","author":"AH Briggs","year":"2003","unstructured":"Briggs AH, Ades A, Price MJ. Probabilistic sensitivity analysis for decision trees with multiple branches: use of the Dirichlet distribution in a Bayesian framework. Med Decis Mak. 2003;23(4):341\u201350.","journal-title":"Med Decis Mak"},{"issue":"9242","key":"923_CR23","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(00)03157-3","volume":"356","author":"C Chiron","year":"2000","unstructured":"Chiron C, Marchand MC, Tran A, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO Study Group. Lancet. 2000;356(9242):1638\u201342.","journal-title":"Lancet"},{"key":"923_CR24","first-page":"155","volume":"43","author":"S Guerrini Tonnelier","year":"2002","unstructured":"Guerrini Tonnelier S, D\u2019Athis P, Rey E, et al. Stiripentol in severe myoclonic epilepsy in infancy (SEMI): a placebo-controlled Italian trial. Epilepsia. 2002;43:155.","journal-title":"Epilepsia."},{"key":"923_CR25","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.eplepsyres.2016.10.006","volume":"128","author":"MS Cooper","year":"2016","unstructured":"Cooper MS, Mcintosh A, Crompton DE, et al. Mortality in Dravet syndrome. Epilepsy Res. 2016;128:43\u20137.","journal-title":"Epilepsy Res"},{"issue":"1","key":"923_CR26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2165\/00019053-200725010-00002","volume":"25","author":"RL Fleurence","year":"2007","unstructured":"Fleurence RL, Hollenbeak CS. Rates and probabilities in economic modelling. Pharmacoeconomics. 2007;25(1):3\u20136.","journal-title":"Pharmacoeconomics"},{"issue":"21","key":"923_CR27","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","volume":"376","author":"O Devinsky","year":"2017","unstructured":"Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376(21):2011.","journal-title":"N Engl J Med"},{"key":"923_CR28","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13643-019-0990-z","volume":"8","author":"J Elliott","year":"2019","unstructured":"Elliott J, McCoy B, Clifford T, et al. Cost-effectiveness of cannabinoids for pediatric drug-resistant epilepsy: protocol for a systematic review of economic evaluations. Syst Rev. 2019;8:75.","journal-title":"Syst Rev"},{"key":"923_CR29","unstructured":"Verdian L, Oyee J, Heyes A, et al. Eliciting preferences for health states associated with Lennox-Gastaut syndrome (LGS) [abstract no. 1.352]. In: Presented at the 62nd meeting of the American Epilepsy Society; Seattle, WA: 5\u20139 Dec 2008."},{"key":"923_CR30","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/978-3-319-15744-3_8","volume-title":"Cost Effectiveness modelling for health technology assessment: a practical course","author":"R Edlin","year":"2015","unstructured":"Edlin R, Mccabe C, Hulme C, et al. Cost effectiveness modelling for health technology assessment: correlated parameters and the Cholesky decomposition. In: Edlin R, Mccabe C, Hulme C, et al., editors. Cost Effectiveness modelling for health technology assessment: a practical course. New York: Springer; 2015. p. 119\u2013132."},{"key":"923_CR31","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.yebeh.2017.12.034","volume":"80","author":"MD Whittington","year":"2018","unstructured":"Whittington MD, Knupp KG, Vanderveen G, et al. The direct and indirect costs of Dravet syndrome. Epilepsy Behav. 2018;80:109\u201313.","journal-title":"Epilepsy Behav"},{"key":"923_CR32","unstructured":"Statistics Canada. Income of individuals by age group, sex and income source, Canada, provinces and selected census metropolitan areas. 2019 [cited 2019]. https:\/\/www.statcan.gc.ca\/."},{"key":"923_CR33","unstructured":"Statistics Canada. The production function approach. 2011 [cited 2019]. https:\/\/www150.statcan.gc.ca\/n1\/pub\/11f0027m\/2008050\/s6-eng.htm. Accessed 8 May 2020."},{"issue":"5","key":"923_CR34","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/epi.13655","volume":"58","author":"BFM Wijnen","year":"2017","unstructured":"Wijnen BFM, van Mastrigt GAPG, Evers SMAA, et al. A systematic review of economic evaluations of treatments for patients with epilepsy. Epilepsia. 2017;58(5):706\u201326.","journal-title":"Epilepsia"},{"issue":"6","key":"923_CR35","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1017\/cjn.2019.282","volume":"46","author":"J Appendino","year":"2019","unstructured":"Appendino J, Boelman C, Brna P, et al. Position statement on the use of medical cannabis for the treatment of epilepsy in Canada. Can J Neurol Sci. 2019;46(6):645\u201352.","journal-title":"Can J Neurol Sci"},{"key":"923_CR36","unstructured":"National Institute for Health and Care Excellence. Single technology appraisal: Cannabidiol for adjuvant treatment of seizures associated with Dravet syndrome. 2019. https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-ta10274\/documents. Accessed 8 May 2020."},{"key":"923_CR37","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.yebeh.2014.08.135","volume":"41","author":"JP Szaflarski","year":"2014","unstructured":"Szaflarski JP, Martina BE. Cannabis, cannabidiol, and epilepsy: from receptors to clinical response. Epilepsy Behav. 2014;41:277\u201382.","journal-title":"Epilepsy Behav"},{"issue":"2","key":"923_CR38","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1155\/2012\/327054","volume":"23","author":"D Coyle","year":"2012","unstructured":"Coyle D, Coyle K, Bettinger JA, et al. Cost effectiveness of infant vaccination for rotavirus in Canada. Can J Infect Dis Med Microbiol. 2012;23(2):71\u20137.","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"923_CR39","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.yebeh.2016.07.034","volume":"63","author":"A Fallah","year":"2016","unstructured":"Fallah A, Weil AG, Wang S, et al. Cost-utility analysis of competing treatment strategies for drug-resistant epilepsy in children with Tuberous Sclerosis Complex. Epilepsy Behav. 2016;63:79\u201388.","journal-title":"Epilepsy Behav"},{"issue":"1","key":"923_CR40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.seizure.2009.10.003","volume":"19","author":"L Verdian","year":"2010","unstructured":"Verdian L, Yi Y. Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox\u2013Gastaut Syndrome in the United Kingdom. Seizure. 2010;19(1):1\u201311.","journal-title":"Seizure"},{"issue":"3","key":"923_CR41","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2165\/11313640-000000000-00000","volume":"28","author":"A Benedict","year":"2010","unstructured":"Benedict A, Verdian L, Maclaine G. The cost effectiveness of rufinamide in the treatment of Lennox\u2013Gastaut syndrome in the UK. Pharmacoeconomics. 2010;28(3):185.","journal-title":"Pharmacoeconomics"},{"key":"923_CR42","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.eplepsyres.2014.12.005","volume":"110","author":"R de Kinderen","year":"2015","unstructured":"de Kinderen R, Postulart D, Aldenkamp AP, et al. Cost-effectiveness of the ketogenic diet and vagus nerve stimulation for the treatment of children with intractable epilepsy. Epilepsy Res. 2015;110:119\u201331.","journal-title":"Epilepsy Res"},{"issue":"18","key":"923_CR43","first-page":"1","volume":"12","author":"J Bowen","year":"2012","unstructured":"Bowen J, Snead O, Chandra K, et al. Epilepsy care in Ontario: an economic analysis of increasing access to epilepsy surgery. Ontario Health Technol Assess Ser. 2012;12(18):1\u201341.","journal-title":"Ontario Health Technol Assess Ser"},{"key":"923_CR44","unstructured":"Ministry of Health and Long-term Care. Ontario Case Costing Initiative. 2017 [cited 2019]. https:\/\/www.ontario.ca\/data\/ontario-case-costing-initiative-occi. Accessed 8 May 2020."},{"key":"923_CR45","unstructured":"Ontario Municipal Benchmarking Initiative. Emergency medical services (EMS): 2013 OMBI Performance Measurement Report. Ontario Municipal Benchmarking Initiative; 2013."},{"key":"923_CR46","unstructured":"Statistics Canada. Employee wages by occupation, annual. 2019 [cited 2019]. https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1410034001. Accessed 8 May 2020."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-020-00923-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-020-00923-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-020-00923-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:18:38Z","timestamp":1620947918000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-020-00923-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,14]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["923"],"URL":"https:\/\/doi.org\/10.1007\/s40273-020-00923-5","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,14]]},"assertion":[{"value":"14 May 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No specific funding was received for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Bl\u00e1thnaid McCoy was principal investigator in a study of cannabinoids for treating epilepsy in children with Dravet syndrome. Jesse Elliott, Tammy Clifford, Beth K. Potter, George A. Wells and Doug Coyle declare they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}